<DOC>
	<DOC>NCT01541111</DOC>
	<brief_summary>This study is an evaluation of the analgesic effect of magnesium associated with morphine in patients with cancer pain.</brief_summary>
	<brief_title>Magnesium Associated With Morphine for Cancer Pain Relief</brief_title>
	<detailed_description>The study is prospective, randomized, double-blind. The patients will be allocated into two groups. After approval by the Ethics Committee and signed informed consent, 40 patients, aged &gt; 18 years of both genders with cancer pain, will be studied. The patients in group 1 (n = 20) will receive a dose of magnesium sulfate (65 mg) po twice daily. Patients in Group 2 (n = 20) will receive placebo twice a day. The Mg and placebo capsules are identical. Everyone will receive morphine as needed. Will be recorded: tumor location, factors which worsen the pain, quality of pain. Pain intensity will be assessed by numerical scale from zero to 10 at T0 (first visit) and after 1, 2, 3. and 4wk. The patient will note the intensity of pain and side effects at home. Functional performance assessment will bes done by the Karnofsky Performance Status Scale. Quality of life will be assessed by the QLQ-c30.</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<criteria>After approval by the Ethics Committee and signed informed consent, 40 patients, &gt; 18 years, with cancer pain, and taking morphine (third step of the analgesic ladder recommended by WHO) were studied Were excluded from the study patients with hypersensitivity to drugs and pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cancer pain</keyword>
	<keyword>Magnesiun</keyword>
</DOC>